From the Nehme and Therese Tohme Multiple Sclerosis Center (M.F.M.), Faculty of Medicine, American University of Beirut Medical Center; Department of Experimental Pathology (E.S.S., L.N.), Immunology and Microbiology, Faculty of Medicine, American University of Beirut; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), and Abu Haidar Neuroscience Institute, Faculty of Medicine, American University of Beirut Medical Center, Lebanon.
Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4). doi: 10.1212/NXI.0000000000001004. Print 2021 Jul.
To investigate in a cross-sectional study the effect of serum-derived exosomes on primary human blood monocyte-derived macrophages (MDMs) comparing exosomes from healthy donors vs patients with relapsing-remitting multiple sclerosis in remission and in relapse and to assess whether the response correlates with exosomal Epstein-Barr virus (EBV) protein expression.
A total of 45 serum-derived exosome preparations were isolated from patients and healthy controls and verified for the expression of exosomal and EBV markers. MDMs were differentiated from monocytes for 7 days and incubated for 24 hours with exosomes, and then, cell supernatants were collected for cytokine measurement by cytometric bead array. Cells were immunophenotyped before and after differentiation.
Serum-derived exosomes of patients with multiple sclerosis (MS) expressed higher levels of EBV proteins than healthy controls. Of interest, expression of EBV nuclear antigen EBNA1 and latent membrane proteins LMP1 and 2A was higher on exosomes derived from patients with active RRMS compared with healthy controls and stable patients. After data normalization, we observed that incubation with EBV(+) exosomes induced CXCL10 and CCL2 secretion by MDMs. MDMs differentiated from patients with active disease were better secretors of CXCL10 and other interferon-γ-inducible chemokines, including CCL2 and CXCL9, than MDMs from healthy and stable MS groups. MDMs from active patients had a higher frequency of a CD14(++) subset that correlated with the secreted CXCL10.
Exosomes expressing EBV proteins correlate with disease activity and induce an inflammatory response in MDMs that is compounded by the origin of the responder cells.
在一项横断面研究中,比较来自缓解期和复发期复发缓解型多发性硬化症患者与健康对照者的血清衍生外泌体对原代人血单核细胞衍生巨噬细胞(MDM)的影响,并评估该反应是否与外泌体 EBV(Epstein-Barr virus)蛋白表达相关。
共分离了 45 份来自患者和健康对照者的血清衍生外泌体制剂,并验证了外泌体和 EBV 标志物的表达。单核细胞分化为 MDM 7 天后,用外泌体孵育 24 小时,然后收集细胞上清液通过流式细胞术微珠阵列检测细胞因子。分化前后对细胞进行免疫表型分析。
多发性硬化症(MS)患者的血清衍生外泌体表达的 EBV 蛋白水平高于健康对照组。有趣的是,与健康对照组和稳定患者相比,处于活动期 RRMS 患者的 EBNA1 和潜伏膜蛋白 LMP1 和 2A 的表达更高。经数据归一化后,我们观察到与 EBV(+)外泌体孵育诱导 MDM 分泌 CXCL10 和 CCL2。与健康对照组和稳定 MS 组相比,来自活动期疾病患者的 MDM 分化后分泌 CXCL10 和其他干扰素-γ诱导趋化因子(包括 CCL2 和 CXCL9)的能力更强。来自活动期患者的 MDM 具有更高频率的 CD14(++)亚群,与分泌的 CXCL10 相关。
表达 EBV 蛋白的外泌体与疾病活动度相关,并在外泌体诱导的 MDM 中诱导炎症反应,而反应者细胞的来源则加剧了这种反应。